Antigen Presentation and Genetic Dynamics Optimization: An Unmodified Quadrivalent mRNA‑LNP Platform Elucidates Potent Innate and Adaptive Immune Induction Mechanisms Relative to Conventional Egg‑Derived Inactivated Vaccines
-
Bottlenecks in egg‑based manufacturing of seasonal influenza vaccines and the blind spot of post‑manufacturing antigen drift. Seasonal influenza continues to impose a global disease burden each year. The standard guideline for defending against influenza relies on conventional inactivated influenza vaccines (IIV). However, currently licensed mainstream vaccines depend on an extremely slow egg‑based production system, creating a lead‑time barrier for antigen supply when a pandemic threat emerges. Moreover, the process of propagating virus in eggs introduces egg‑adaptation mutations that generate structural mismatches between the circulating strain and the vaccine antigen, undermining the effective neutralization threshold of humoral immunity. The absence of a rapid, programmable platform capable of responding instantly to variant influenza strains has been a chronic technical bottleneck and blind spot in global health security.
-
Unmodified quadrivalent mRNA‑LNP architecture: encoding HA genes and accelerating innate immunity. To neutralize the chronic production delays and antigenic drift barriers, we deployed an unmodified mRNA‑LNP vaccine platform encoding the hemagglutinin (HA) genes of four seasonal influenza strains—two influenza A subtypes (H1N1, H3N2) and two influenza B lineages (Phuket, Colorado). A head‑to‑head non‑human primate (NHP) benchmark was performed against commercial vaccines (Vaxigrip, Fluad). By deliberately avoiding nucleoside modifications, the native mRNA backbone was designed to act as a potent adjuvant that strongly stimulates intracellular pattern‑recognition receptors TLR7/8. The LNP‑encapsulated payload triggered an immediate computational expansion of intermediate monocytes and rapidly up‑regulated transcriptional programs related to antiviral defense, antigen presentation, and cell‑migration pathways, thereby activating a distinctive early innate immune system.
-
Exponential amplification and affinity maturation of memory B‑ and T‑cell pools in draining lymph nodes. Kinetic tracking of humoral and cellular adaptive immune layers demonstrated that the mRNA vaccine elicited HA‑specific serum antibody responses that were comparable to or exceeded those induced by conventional inactivated vaccines across all four influenza strains. Notably, the structural scaffold of this platform promoted sustained antigen presentation, leading to a dramatic increase in the differentiation frequency of HA‑specific memory B cells and memory T cells within draining lymph nodes. This goes beyond the limitation of traditional vaccines that merely maintain circulating antibody levels; by stimulating germinal‑center reactions, the platform establishes a high‑resolution immunological backbone capable of genetically driving antibody diversity and affinity maturation upon encounter with future variant strains.
-
Establishing next‑generation universal influenza vaccine standards and an in‑silico mass‑production pipeline. The immunological and nucleic‑acid delivery dataset generated by this study offers a uniquely impactful asset for global next‑generation biopharma R&D and pandemic‑response governance. It resets the production paradigm from months‑long egg‑based culture to a digital plug‑and‑play infrastructure that can virtually synthesize and manufacture a quadrivalent antigen set within days after receiving sequence data. The derived lymph‑node memory‑cell activation weighting matrix will serve as a computational filter standard for eliminating false‑positive immune‑non‑responsiveness noise in forthcoming human trials. Consequently, this asset can serve as a master reference to eliminate strain mismatch in seasonal influenza vaccines and to dramatically shorten regulatory timelines for next‑generation nucleic‑acid‑based universal antigen IND approvals.
Oncology & Infectious Disease Core, Published May 2026. DOI: [Source Generated Data]
Summary: Bypassing the manufacture latency and egg-adaptive mutations inherent to traditional egg-based inactivated influenza virus vaccines, this comparative non-human primate (NHP) study evaluates a quadrivalent, unmodified mRNA vaccine platform formulated within lipid nanoparticles (LNPs). Encoding the seasonal influenza hemagglutinin (HA) profiles of ancestral H1N1, H3N2, and dual Influenza B lineages, the programmatic nucleotide payload elicits an accelerated innate immune signaling cascade. Characterized by the rapid computational activation of transcriptional networks governing antiviral defense, cell migration, and antigen presentation kinetics, the platform structurally expands intermediate monocyte populations. Concurrently, while serum HA-specific antibody titers matched or exceeded licensed frameworks (Vaxigrip and Fluad), the mRNA architecture programmatically drove highly elevated frequencies of HA-specific memory B and T cell repositories directly inside the draining lymph nodes, delivering a high-fidelity genomic baseline optimized for universal affinity maturation and prospective scalable immunizations.
This study provides a top‑tier R&D asset that mathematically quantifies, via primate preclinical omics profiling, the two major challenges in influenza immunology—the antigenic drift induced by egg‑based cultivation and the suboptimal memory T/B‑cell differentiation efficiency of conventional vaccines. It includes quantitative metrics such as the fold‑change amplification of monocyte transcriptomes and the kinetic constants describing the persistence of memory cell populations in lymph nodes following administration of the quadrivalent antigen set. Consequently, the dataset serves as a powerful, exclusive reference for advancing AI‑driven next‑generation universal nucleic‑acid vaccine epitope‑design algorithms and for elevating the molecular design resolution of global bio‑defense vaccine supply‑chain optimization pipelines to world‑leading specifications.